论文部分内容阅读
甲硝哒唑是硝基咪唑的一种衍生物。1964年Davis等首次发现其口服制剂能抗厌氧菌感染,并为后人所证实。本品60～80%从肾脏排出,6～15%从粪便排出。静注7.5mg/kg,血清中最高浓度达20～25μg/ml。口服后1小时内至少吸收80%。肝功能不全者血浆浓度可显著升高,故剂量应酌量减少。肾功能不全者对本品的药物动力学影响甚微。血液透析可彻底清除本品及其代谢产物。蛋白结合率低于20%。本品能很好地扩散到全身组织,在脑脊液、胆汁、骨及脓肿内迅速达到杀菌浓度。临床实践:本品对其敏感的厌氧菌引起
Metronidazole is a derivative of nitroimidazole. In 1964, Davis et al found for the first time that oral preparations were resistant to anaerobic infections and confirmed by future generations. This product 60 to 80% from the kidneys, 6 ~ 15% from the excretion. Intravenous injection of 7.5mg / kg, the highest serum concentration of 20 ~ 25μg / ml. At least 80% absorption within 1 hour after oral administration. The plasma concentration of liver dysfunction can be significantly increased, so the dose should be reduced. Renal dysfunction on the pharmacokinetics of this product has little effect. Hemodialysis can completely remove the product and its metabolites. Protein binding rate of less than 20%. This product can well spread to the body tissue, in cerebrospinal fluid, bile, bone and abscess rapidly reached the bactericidal concentration. Clinical practice: This product is caused by its sensitive anaerobic bacteria